| For: | Chamchoum E, Katrib N, Nassif N, Ratel Y, Rida MA. Glucagon-like peptide and its receptor agonists for the treatment of rheumatic diseases. World J Exp Med 2025; 15(3): 107020 [PMID: 41523775 DOI: 10.5493/wjem.v15.i3.107020] |
|---|---|
| URL: | https://www.wjgnet.com/2220-315X/full/v15/i3/107020.htm |
| Number | Citing Articles |
| 1 |
Ronit E. Malka, Sam Collins, Vasiliki Triantafillou, Niloufar Saeedi, Lee M. Akst, Simon R. Best, Kevin Motz, Alexander T. Hillel. GLP‐1 Receptor Agonist Effect on Disease Severity in Idiopathic Subglottic Stenosis. Otolaryngology–Head and Neck Surgery 2026; doi: 10.1002/ohn.70327
|
| 2 |
Cole J. Dennis, Arianna Z. He, Aishwarya Krishnaraj, Adrian Quan, Hwee Teoh, Kim A. Connelly, David A. Hess, Subodh Verma. Prevention of Vascular Aging as a Novel Paradigm for GLP-1 Receptor Agonist–Mediated Cardioprotection. Circulation Research 2026; 139(3) doi: 10.1161/CIRCRESAHA.126.327425
|
| 3 |
Anastasia Voznesenskaya, Alyona Sorokina, Marina Shestakova, Ekaterina Shestakova, Ildar Minniakhmetov, Anna Ivanova, Sergey Rumyantsev, Natalia Mokrysheva, Vladimir Chekhonin, Marina Loguinova. From Metabolically Healthy to Unhealthy Obesity Through Low-Grade Inflammation. Biomedicines 2026; 14(5) doi: 10.3390/biomedicines14051161
|
| 4 |
Robin Sia, Ee Lynn Ting, Suet-Wan Choy, Shereen Oon. GLP-1 receptor agonists in systemic lupus erythematosus: a scoping review. RMD Open 2026; 12(3) doi: 10.1136/rmdopen-2026-007037
|